Skip to content

Frazier SPAC Is in Talks to Merge With NewAmsterdam Pharma

  • Transaction would value combined company at $700 million
  • Netherlands-based pharma working to treat metabolic diseases

NewAmsterdam Pharma BV, a biotechnology company that aims to treat metabolic diseases, is in talks to go public through a merger with blank-check firm Frazier Lifesciences Acquisition Corp., according to people with knowledge of the matter. 

Frazier, a Seattle-based special purpose acquisition company led by Chairman and Chief Executive Officer Jamie Topper, is in final discussions with investors for a private investment in public equity to support a transaction that’s set to value the combined entity at more than $700 million, said some of the people, all of whom requested anonymity as the talks are private. As with all transactions that have not been finalized, it’s possible talks could collapse.